Review

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics

  1. Joshua J. Coon1,2,†,
  2. Petra Zürbig Dr.3,†,*,
  3. Mohammed Dakna3,
  4. Anna F. Dominiczak4,
  5. Stéphane Decramer5,6,7,
  6. Danilo Fliser8,‡,
  7. Moritz Frommberger9,
  8. Igor Golovko3,
  9. David M. Good1,
  10. Stefan Herget-Rosenthal10,‡,
  11. Joachim Jankowski11,‡,
  12. Bruce A. Julian12,
  13. Markus Kellmann13,
  14. Walter Kolch14,
  15. Ziad Massy15,‡,
  16. Jan Novak12,
  17. Kasper Rossing16,
  18. Joost P. Schanstra5,6,
  19. Eric Schiffer3,
  20. Dan Theodorescu17,
  21. Raymond Vanholder18,‡,
  22. Eva M. Weissinger19,‡,
  23. Harald Mischak3,‡,
  24. Philippe Schmitt-Kopplin9

Article first published online: 10 JUL 2008

DOI: 10.1002/prca.200800024

Issue

PROTEOMICS - Clinical Applications

PROTEOMICS - Clinical Applications

Volume 2, Issue 7-8, pages 964–973, No. 7-8 July 2008

Additional Information

How to Cite

Coon, J. J., Zürbig, P., Dakna, M., Dominiczak, A. F., Decramer, S., Fliser, D., Frommberger, M., Golovko, I., Good, D. M., Herget-Rosenthal, S., Jankowski, J., Julian, B. A., Kellmann, M., Kolch, W., Massy, Z., Novak, J., Rossing, K., Schanstra, J. P., Schiffer, E., Theodorescu, D., Vanholder, R., Weissinger, E. M., Mischak, H. and Schmitt-Kopplin, P. (2008), CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Prot. Clin. Appl., 2: 964–973. doi: 10.1002/prca.200800024

Author Information

  1. 1

    Department of Chemistry, University of Wisconsin-Madison, Madison, WI, USA

  2. 2

    Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA

  3. 3

    Mosaiques diagnostics & therapeutics, Hannover, Germany

  4. 4

    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK

  5. 5

    Department of Renal and Cardiac Remodelling, Inserm, U858/I2MR, Toulouse, France

  6. 6

    Université Toulouse III Paul Sabatier, Institut de Médecine Moléculaire de Rangueil, Toulouse, France

  7. 7

    Pediatric Nephrology Unit, Hopital des Enfants, CHU de Toulouse, Toulouse, France

  8. 8

    Department of Nephrology, Hannover Medical School, Hannover, Germany

  9. 9

    Department of Ecological Chemistry, Helmholtz Center Munich – German Research Center for Health and Environment, Neuherberg, Germany

  10. 10

    Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

  11. 11

    Nephrology Departement, Charité Hospital, Berlin, Germany

  12. 12

    University of Alabama at Birmingham, Birmingham, AL, USA

  13. 13

    Thermo Fisher Scientific, Bremen, Germany

  14. 14

    The Beatson Institute for Cancer Research & Sir Henry Wellcome Functional Genomics Facility, University of Glasgow, Glasgow, UK

  15. 15

    Departments of Clinical Pharmacology and Nephrology, INSERM, ERI-12, and Amiens University Hospital, UPJV, Amiens, France

  16. 16

    Steno Diabetes Centre, Gentofte, Denmark

  17. 17

    Department of Urology, University of Virginia, Charlottesville, VA, USA

  18. 18

    Department of Internal Medicine, University Hospital Ghent, Ghent, Belgium

  19. 19

    Department of Hematology, Hemostasis and Oncology, Hannover Medical School, Hannover, Germany

  1. †

    Both these authors have contributed equally to this work.

  2. ‡

    On behalf of the EUTox consortium.

*Mosaiques diagnostics & therapeutics AG, Mellendorfer Str. 7-9, 30625 Hannover, Germany Fax: +49-511-554744-31

  1. †

    Both these authors have contributed equally to this work.

  2. ‡

    On behalf of the EUTox consortium.

Publication History

  1. Issue published online: 21 JUL 2008
  2. Article first published online: 10 JUL 2008
  3. Manuscript Received: 17 JAN 2008

Funded by

  • BioProfil ‘Funktionelle Genomanalyse’
  • Lower Saxony Ministry of Economy
  • Eurotransbio
  • European Union
  • PREDICTIONS
  • InGenious HyperCare
  • British Heart Foundation
  • Wellcome Trust
  • NIH
  • General Clinical Research Centre of the University of Alabama at Birmingham

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (380K)

Keywords:

  • CE;
  • Database;
  • MS;
  • Urine

Abstract

Owing to its availability, ease of collection, and correlation with pathophysiology of diseases, urine is an attractive source for clinical proteomics. However, many proteomic studies have had only limited clinical impact, due to factors such as modest numbers of subjects, absence of disease controls, small numbers of defined biomarkers, and diversity of analytical platforms. Therefore, it is difficult to merge biomarkers from different studies into a broadly applicable human urinary proteome database. Ideally, the methodology for defining the biomarkers should combine a reasonable analysis time with high resolution, thereby enabling the profiling of adequate samples and recognition of sufficient features to yield robust diagnostic panels. CE-MS, which was used to analyze urine samples from healthy subjects and patients with various diseases, is a suitable approach for this task. The database of these datasets compiled from the urinary peptides enables the diagnosis, classification, and monitoring of a wide range of diseases. CE-MS exhibits excellent performance for biomarker discovery and allows subsequent biomarker sequencing independent of the separation platform. This approach may elucidate the pathogenesis of many diseases, and better define especially renal and urological disorders at the molecular level.

Get PDF (380K)